|
1
|
Marcia LL, Brian PR, Tara LB, et al: KIT
extracellular and kinase domain mutations in gastrointestinal
stromal tumors. Am J Pathol. 156:791–795. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Matei D, Chang DD and Jeng MH: Imatinib
mesylate (Gleevec) inhibits ovarian cancer cell growth through a
mechanism dependent on platelet-derived growth factor receptor
alpha and Akt inactivation. Clin Cancer Res. 10:681–690. 2004.
View Article : Google Scholar
|
|
3
|
Malaise M, Steinbach D and Corbacioglu S:
Clinical implications of c-Kit mutations in acute myelogenous
leukemia. Curr Hematol Malig Rep. 4:77–82. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Chi P, Chen Y, Zhang L, et al: ETV1 is a
lineage survival factor that cooperates with KIT in
gastrointestinal stromal tumours. Nature. 467:849–853. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Schneider BJ, Kalemkerian GP, Ramnath N,
et al: Phase II trial of imatinib maintenance therapy after
irinotecan and cisplatin in patients with c-Kit-positive,
extensive-stage small-cell lung cancer. Clin Lung Cancer.
11:223–227. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Schmandt RE, Broaddus R, Lu KH, et al:
Expression of c-ABL, c-KIT, and platelet-derived growth factor
receptor-beta in ovarian serous carcinoma and normal ovarian
surface epithelium. Cancer. 98:758–764. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Henriksen R, Funa K, Wilander E, Bäckström
T, Ridderheim M and Oberg K: Expression and prognostic significance
of platelet-derived growth factor and its receptors in epithelial
ovarian neoplasms. Cancer Res. 53:4550–4554. 1993.PubMed/NCBI
|
|
8
|
Lassus H, Sihto H, Leminen A, Nordling S,
Joensuu H, Nupponen NN and Butzow R: Genetic alterations and
protein expression of KIT and PDGFRA in serous ovarian carcinoma.
Br J Cancer. 91:2048–2055. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Yi CJ, Lin SR and Chen KM: Expression and
clinical significance of c-kit and PDGFRa in ovarian serous
carcinomas. Chinese Journal of Gynecology and Obstetrics.
22:295–296. 2006.
|
|
10
|
Parrott JA, Kim G and Skinner MK:
Expression and action of kit ligand/stem cell factor in normal
human and bovine ovarian surface epithelium and ovarian cancer.
Biol Reprod. 62:1600–1609. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Tonary AM, Macdonald EA, Faught W,
Senterman MK and Vanderhyden BC: Lack of expression of c-KIT in
ovarian cancers is associated with poor prognosis. Int J Cancer.
89:242–250. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Arber DA, Tamayo R and Weiss LM: Paraffin
section detection of the c-Kit gene product (CD117) in human
tissues: value in the diagnosis of mast cell disorders. Hum Pathol.
29:498–504. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Singer G, Schraml P, Belgard C, et al: KIT
in ovarian carcinoma: disillusion about a potential therapeutic
target. J Natl Cancer Inst. 95:1009–1010. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Dabrow MB, Francesco MR, McBrearty FX and
Caradonna S: The effects of platelet-derived growth factor and
receptor on normal and neoplastic human ovarian surface epithelium.
Gynecol Oncol. 71:29–37. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Apte SM, Bucana CD, Killion JJ, Gershenson
DM and Fidler IJ: Expression of platelet-derived growth factor and
activated receptor in clinical specimens of epithelial ovarian
cancer and ovarian carcinoma cell lines. Gynecol Oncol. 93:78–86.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Vigne JL, Halburnt LL and Skinner MK:
Characterization of bovine ovarian surface epithelium and stromal
cells: identification of secreted proteins. Biol Reprod.
51:1213–1221. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Baranowska-Kortylewicz J, Abe M, Pietras
K, et al: Effect of platelet-derived growth factor receptor-beta
inhibition with STI571 on radioimmunotherapy. Cancer Res.
65:7824–7831. 2005.PubMed/NCBI
|
|
18
|
Yu J, Moon A and Kim HR: Both
platelet-derived growth factor receptor (PDGFR)-alpha and
PDGFR-beta promote murine fibroblast cell migration. Biochem
Biophys Res Commun. 282:697–700. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Bergers G, Song S, Meyer-Morse N,
Bergsland E and Hanahan D: Benefits of targeting both pericytes and
endothelial cells in the tumor vasculature with kinase inhibitors.
J Clin Invest. 111:1287–1295. 2003. View Article : Google Scholar : PubMed/NCBI
|
